Quantcast

Latest Oncotype DX Stories

2014-01-29 08:30:07

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype DX(®) colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the...

2014-01-28 08:29:34

REDWOOD CITY, Calif., Jan. 28, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 4 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2013 financial results. The call and webcast will follow the release of the fourth quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call DetailsTo access the live...

2014-01-07 08:30:40

- Agreement to Distribute Oncotype DX(R) in Australia and New Zealand MELBOURNE, Australia, Jan. 7, 2014 /PRNewswire/ -- Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc. (NASDAQ: GHDX). STA has struck an agreement to represent the important...

2014-01-06 16:27:41

REDWOOD CITY, Calif., Jan. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Genomic Health's Chairman, Chief Executive Officer, and President will present at the 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8:30 a.m. Pacific Time (PT). To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at...

2013-12-12 10:49:59

Genetic signature identifies patients with more aggressive triple-negative cancers A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, described in the Dec. 11 issue of PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related